11 July 2024
Dr. Martens plc - AGM Trading Update
Today, Dr. Martens plc will hold its annual general meeting at 09.30 at the Holiday Inn London, Camden Lock, 30 Jamestown Road, London.
Trading since the start of this financial year has been in line with expectations and our guidance for FY25 remains unchanged. As always, Q1 is the smallest period of our financial year, representing the end of the Spring/Summer season. As communicated in our recent FY24 results, the current financial year will be very second-half weighted, particularly from a profit perspective.
The upcoming Autumn/Winter 24 season remains a key focus and detailed trading plans, as discussed in our recent FY24 results, are being implemented. We continue to target positive DTC growth in the USA in H2. Work on our cost action plan is ongoing and we will provide a detailed update at our first half results in November.
Enquiries
Investors and analysts
Bethany Barnes, Director of Investor Relations +44 7825 187465
bethany.barnes@drmartens.com
Beth Callum, Investor Relations Manager beth.callum@drmartens.com
Press
Gill Hammond, Director of Communications +44 7384 214248
H/Advisors Maitland +44 20 7379 5151
Katharine Spence +44 7384 535739
About Dr. Martens
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude.
The Company listed successfully on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
